[1]
Arora A,Potter JF, Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer. Journal of the American Geriatrics Society. 2004 Apr; [PubMed PMID: 15066080]
[2]
Brueggemeier RW,Hackett JC,Diaz-Cruz ES, Aromatase inhibitors in the treatment of breast cancer. Endocrine reviews. 2005 May [PubMed PMID: 15814851]
[3]
Burstein HJ,Temin S,Anderson H,Buchholz TA,Davidson NE,Gelmon KE,Giordano SH,Hudis CA,Rowden D,Solky AJ,Stearns V,Winer EP,Griggs JJ, Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Jul 20; [PubMed PMID: 24868023]
[4]
Paridaens RJ,Dirix LY,Beex LV,Nooij M,Cameron DA,Cufer T,Piccart MJ,Bogaerts J,Therasse P, Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Oct 20; [PubMed PMID: 18794551]
[5]
Simpson D,Curran MP,Perry CM, Letrozole: a review of its use in postmenopausal women with breast cancer. Drugs. 2004; [PubMed PMID: 15161328]
[6]
Miller WR,Jackson J, The therapeutic potential of aromatase inhibitors. Expert opinion on investigational drugs. 2003 Mar; [PubMed PMID: 12605559]
[7]
Behan LA,Amir E,Casper RF, Aromatase inhibitors for prevention of breast cancer in postmenopausal women: a narrative review. Menopause (New York, N.Y.). 2015 Mar [PubMed PMID: 25692874]
[8]
Bedaiwy MA,Mousa NA,Casper RF, Aromatase inhibitors: potential reproductive implications. Journal of minimally invasive gynecology. 2009 Sep-Oct; [PubMed PMID: 19608462]
[10]
Zagouri F,Sergentanis TN,Azim HA Jr,Chrysikos D,Dimopoulos MA,Psaltopoulou T, Aromatase inhibitors in male breast cancer: a pooled analysis. Breast cancer research and treatment. 2015 May; [PubMed PMID: 25850534]
[11]
Tan RB,Guay AT,Hellstrom WJ, Clinical Use of Aromatase Inhibitors in Adult Males. Sexual medicine reviews. 2014 Apr; [PubMed PMID: 27784593]
[13]
Blakemore J,Naftolin F, Aromatase: Contributions to Physiology and Disease in Women and Men. Physiology (Bethesda, Md.). 2016 Jul; [PubMed PMID: 27252161]
[14]
Nabholtz JM, Long-term safety of aromatase inhibitors in the treatment of breast cancer. Therapeutics and clinical risk management. 2008 Feb; [PubMed PMID: 18728707]
[15]
Forbes JF, The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial. Seminars in oncology. 2006 Apr; [PubMed PMID: 16730270]
[16]
Słopień R,Męczekalski B, Aromatase inhibitors in the treatment of endometriosis. Przeglad menopauzalny = Menopause review. 2016 Mar; [PubMed PMID: 27095958]
[17]
Abu Hashim H, Potential role of aromatase inhibitors in the treatment of endometriosis. International journal of women's health. 2014; [PubMed PMID: 25092998]
[18]
de Ronde W,de Jong FH, Aromatase inhibitors in men: effects and therapeutic options. Reproductive biology and endocrinology : RB [PubMed PMID: 21693046]
[19]
Cuzick J,Sestak I,Baum M,Buzdar A,Howell A,Dowsett M,Forbes JF, Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. The Lancet. Oncology. 2010 Dec; [PubMed PMID: 21087898]
[20]
Sini V,Botticelli A,Lunardi G,Gori S,Marchetti P, Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients. Pharmacogenomics. 2017 Jun; [PubMed PMID: 28592202]
[21]
Krásenská M, [Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects]. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 2016 Fall; [PubMed PMID: 28118723]
[22]
Foglietta J,Inno A,de Iuliis F,Sini V,Duranti S,Turazza M,Tarantini L,Gori S, Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients. Clinical breast cancer. 2017 Feb; [PubMed PMID: 27561703]
[24]
Tiboni GM,Ponzano A, Fetal safety profile of aromatase inhibitors: Animal data. Reproductive toxicology (Elmsford, N.Y.). 2016 Dec; [PubMed PMID: 27697604]
[25]
Van Poznak C,Makris A,Clack G,Barlow DH,Eastell R, Lipid profiles within the SABRE trial of anastrozole with and without risedronate. Breast cancer research and treatment. 2012 Aug; [PubMed PMID: 22763465]
[26]
Gonnelli S,Petrioli R, Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer. Clinical interventions in aging. 2008; [PubMed PMID: 19281057]
[27]
Jonat W,Howell A,Blomqvist C,Eiermann W,Winblad G,Tyrrell C,Mauriac L,Roche H,Lundgren S,Hellmund R,Azab M, A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. European journal of cancer (Oxford, England : 1990). 1996 Mar; [PubMed PMID: 8814682]